All

API

FDF

Price

Services

Excipients

Enquiries

Find

Active Pharmaceutical Ingredients
Finished Drug Formulations
Price
Excipients
Services
Marketplace

Market Place

Post Enquiry

Grow Your Pharma Business Digitally

pipeline-prospector-insert

X

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

All Data

Filters

refresh

×

FILTER DATA :

News Type

Company

Product Type

Deal Size

Upfront Payment

refresh

Product Type

Companies

Oncology Venture

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

DENMARK Denmark

Post An Enquiry

IFT Annual Expo

Participation Not Confirmed

Update your events

Oncology Venture Acquires Full Control of Dovitinib Program

Contact the Supplier

Lead Product(s): Dovitinib

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase III Product Type: Small molecule

Partner/Sponsor/Collaborator: Sass & Larsen ApS

Deal Size: $4.0 million Upfront Cash: Undisclosed

Deal Type: Agreement June 08, 2020

Details:

Oncology Venture has acquired the remaining 37% ownership in its priority Dovitinib program from investor Sass & Larsen ApS. As a result of the transaction, the Company now has full control of its most advanced pipeline program.